PMID- 27535548
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20181113
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 16
DP  - 2016 Aug 17
TI  - Type 2 diabetes mellitus and risk of colorectal adenoma: a meta-analysis of 
      observational studies.
PG  - 642
LID - 10.1186/s12885-016-2685-3 [doi]
LID - 642
AB  - BACKGROUND: To summarize the relationship between type 2 diabetes mellitus (T2DM) 
      and risk of colorectal adenomas (CRA), we performed a meta-analysis of 
      observational studies. METHODS: To find studies, we searched PubMed, Embase, the 
      Cochrane Library, Web of Science and conference abstracts and related 
      publications for American Society of Clinical Oncology and the European Society 
      of Medical Oncology. Studies that reported relative risks (RRs) or odds ratios 
      (ORs) with 95 % confidence intervals (CIs) for the association between T2DM and 
      risk of CRA were included. The meta-analysis assessed the relationships between 
      T2DM and risk of CRA. Sensitivity analyses were performed in two ways: (1) by 
      omitting each study iteratively and (2) by keeping high-quality studies only. 
      Publication bias was detected by Egger's and Begg's tests and corrected using the 
      trim and fill method. RESULTS: This meta-analysis included 17 studies with 28,999 
      participants and 6798 CRA cases. We found that T2DM was a risk factor for CRA 
      (RR: 1.52; 95 % CI: 1.29-1.80), and also for the advanced adenoma (RR: 1.41; 95 % 
      CI: 1.06-1.87). Patients with existing T2DM (RR: 1.56; 95 % CI: 1.16-2.08) or 
      newly diagnosed T2DM (RR: 1.51; 95 % CI: 1.16-1.97) have a risk of CRA. Similar 
      significant results were found in retrospective studies (RR: 1.57; 95 % CI: 
      1.30-1.89) and population based cross-sectional studies (RR: 1.46; 95 % CI: 
      1.21-1.89), but not in prospective studies (RR: 1.27; 95 % CI: 0.77-2.10). 
      CONCLUSIONS: Our results suggested that T2DM plays a risk role in the risk of 
      developing CRA. Consequently, medical workers should increase the rate of CRA 
      screening for T2DM patients so that they can benefit from behavioural 
      interventions that can help prevent the development of colorectal cancer. 
      Additional, large prospective cohort studies are needed to make a more convincing 
      case for these associations.
FAU - Yu, Feifei
AU  - Yu F
AD  - Medical Service Research Division, Navy Medical Research Institute, Shanghai, 
      China.
FAU - Guo, Yibin
AU  - Guo Y
AD  - Department of Health Statistics, Second Military Medical University, No. 800 
      Xiangyin Road, Shanghai, 200433, China.
FAU - Wang, Hao
AU  - Wang H
AD  - Department of Colorectal Surgery, Changhai Hospital, Shanghai, China.
FAU - Feng, Jian
AU  - Feng J
AD  - Department of Health Statistics, Second Military Medical University, No. 800 
      Xiangyin Road, Shanghai, 200433, China.
FAU - Jin, Zhichao
AU  - Jin Z
AD  - Department of Health Statistics, Second Military Medical University, No. 800 
      Xiangyin Road, Shanghai, 200433, China.
FAU - Chen, Qi
AU  - Chen Q
AD  - Department of Health Statistics, Second Military Medical University, No. 800 
      Xiangyin Road, Shanghai, 200433, China.
FAU - Liu, Yu
AU  - Liu Y
AD  - College of Art & Science, University of San Francisco, San Francisco, USA.
FAU - He, Jia
AU  - He J
AD  - Department of Health Statistics, Second Military Medical University, No. 800 
      Xiangyin Road, Shanghai, 200433, China. hejia63@yeah.net.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20160817
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Insulin)
SB  - IM
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/*epidemiology
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Insulin/*adverse effects/therapeutic use
MH  - Male
MH  - Observational Studies as Topic
MH  - Risk Factors
PMC - PMC4989384
OTO - NOTNLM
OT  - Colorectal adenoma
OT  - Meta-analysis
OT  - Type 2 diabetes mellitus
EDAT- 2016/08/19 06:00
MHDA- 2017/09/28 06:00
PMCR- 2016/08/17
CRDT- 2016/08/19 06:00
PHST- 2014/11/01 00:00 [received]
PHST- 2016/08/05 00:00 [accepted]
PHST- 2016/08/19 06:00 [entrez]
PHST- 2016/08/19 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
PHST- 2016/08/17 00:00 [pmc-release]
AID - 10.1186/s12885-016-2685-3 [pii]
AID - 2685 [pii]
AID - 10.1186/s12885-016-2685-3 [doi]
PST - epublish
SO  - BMC Cancer. 2016 Aug 17;16:642. doi: 10.1186/s12885-016-2685-3.